IE32343B1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number: IE32343B1
Authority: IE; Ireland
Prior art keywords: medicament; particle size; carrier; powder; effective particle
Prior art date: 1967-08-08

Application number

IE898/68A

Other languages

English (en)

Other versions

IE32343L (en

Original Assignee

Fisons Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1967-08-08

Filing date

1968-07-25

Publication date

1973-06-27

1968-07-25 Application filed by Fisons Pharmaceuticals Ltd filed Critical Fisons Pharmaceuticals Ltd

1968-07-25 Priority to IE163/73A priority Critical patent/IE32872B1/xx

1969-02-08 Publication of IE32343L publication Critical patent/IE32343L/xx

1973-06-27 Publication of IE32343B1 publication Critical patent/IE32343B1/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
239000003814 drug Substances 0.000 abstract 7
239000002245 particle Substances 0.000 abstract 7
239000000203 mixture Substances 0.000 abstract 5
239000000843 powder Substances 0.000 abstract 4
239000007787 solid Substances 0.000 abstract 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 abstract 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
239000002775 capsule Substances 0.000 abstract 2
239000011248 coating agent Substances 0.000 abstract 2
238000000576 coating method Methods 0.000 abstract 2
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 abstract 2
239000003085 diluting agent Substances 0.000 abstract 2
239000008101 lactose Substances 0.000 abstract 2
238000002156 mixing Methods 0.000 abstract 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 abstract 1
ZOLBALGTFCCTJF-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 ZOLBALGTFCCTJF-UHFFFAOYSA-N 0.000 abstract 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
229920002307 Dextran Polymers 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
108010010803 Gelatin Proteins 0.000 abstract 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
229930182555 Penicillin Natural products 0.000 abstract 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 1
235000021355 Stearic acid Nutrition 0.000 abstract 1
239000000150 Sympathomimetic Substances 0.000 abstract 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
239000004098 Tetracycline Substances 0.000 abstract 1
229960004308 acetylcysteine Drugs 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000002804 anti-anaphylactic effect Effects 0.000 abstract 1
230000001387 anti-histamine Effects 0.000 abstract 1
239000000739 antihistaminic agent Substances 0.000 abstract 1
230000003115 biocidal effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000002425 crystallisation Methods 0.000 abstract 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
239000006185 dispersion Substances 0.000 abstract 1
229960002179 ephedrine Drugs 0.000 abstract 1
229920000159 gelatin Polymers 0.000 abstract 1
239000008273 gelatin Substances 0.000 abstract 1
235000019322 gelatine Nutrition 0.000 abstract 1
235000011852 gelatine desserts Nutrition 0.000 abstract 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
229960001317 isoprenaline Drugs 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
230000000510 mucolytic effect Effects 0.000 abstract 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
229940049954 penicillin Drugs 0.000 abstract 1
229920003023 plastic Polymers 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
238000001556 precipitation Methods 0.000 abstract 1
238000001694 spray drying Methods 0.000 abstract 1
239000008117 stearic acid Substances 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1
230000001975 sympathomimetic effect Effects 0.000 abstract 1
229960002180 tetracycline Drugs 0.000 abstract 1
229930101283 tetracycline Natural products 0.000 abstract 1
235000019364 tetracycline Nutrition 0.000 abstract 1
150000003522 tetracyclines Chemical class 0.000 abstract 1
239000011782 vitamin Substances 0.000 abstract 1
229940088594 vitamin Drugs 0.000 abstract 1
229930003231 vitamin Natural products 0.000 abstract 1
235000013343 vitamin Nutrition 0.000 abstract 1
150000003722 vitamin derivatives Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Fastening Of Light Sources Or Lamp Holders (AREA)

IE898/68A 1967-08-08 1968-07-25 Pharmaceutical composition IE32343B1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IE163/73A IE32872B1 (en)	1967-08-08	1968-07-25	Drug for use in pharmaceutical composition

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB36270/67A GB1242211A (en)	1967-08-08	1967-08-08	Pharmaceutical composition

Publications (2)

Publication Number	Publication Date
IE32343L IE32343L (en)	1969-02-08
IE32343B1 true IE32343B1 (en)	1973-06-27

Family

ID=10386572

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE898/68A IE32343B1 (en)	1967-08-08	1968-07-25	Pharmaceutical composition

Country Status (14)

Country	Link
US (1)	US3634582A (2)
JP (1)	JPS5643448B1 (2)
BE (1)	BE718846A (2)
CA (1)	CA946280A (2)
DE (2)	DE1792207C3 (2)
DK (1)	DK123276B (2)
FI (1)	FI48973C (2)
FR (2)	FR8142M (2)
GB (1)	GB1242211A (2)
IE (1)	IE32343B1 (2)
MY (2)	MY7400329A (2)
NL (1)	NL161984C (2)
NO (1)	NO128307B (2)
SE (1)	SE372420B (2)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1381872A (en) *	1971-06-22	1975-01-29	Fisons Ltd	Pharmaceutical compositions for inhalation
BE787100A (fr) *	1971-08-06	1973-02-02	Beecham Group Ltd	Composition pour le traitement de l'asthme
GB1410588A (en) *	1971-08-10	1975-10-22	Fisons Ltd	Composition
DE2332663C2 (de) *	1973-06-23	1986-07-31	Schering AG, 1000 Berlin und 4709 Bergkamen	Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
DE2535258C2 (de) *	1974-08-10	1993-06-03	Fisons Plc, Ipswich, Suffolk	Inhalierbares Medikament in Pelletform
US4161516A (en) *	1975-07-25	1979-07-17	Fisons Limited	Composition for treating airway disease
FI770215A7 (2) *	1976-01-30	1977-07-31	Fisons Ltd
GB2077100B (en) *	1980-04-30	1985-04-24	Fisons Ltd	Pharmaceutical compositions containing cromoglycates
BE891013A (fr) *	1980-11-05	1982-05-05	Fisons Ltd	Compositions pharmaceutique
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
ATE77947T1 (de) *	1987-04-09	1992-07-15	Fisons Plc	Pentamidin enthaltende pharmazeutische zusammensetzungen.
US5204113A (en) *	1987-04-09	1993-04-20	Fisons Plc	Pharmaceutical compositions containing pentamidine
DE4140689B4 (de) *	1991-12-10	2007-11-22	Boehringer Ingelheim Kg	Inhalationspulver und Verfahren zu ihrer Herstellung
CA2115444C (en) *	1992-06-12	2000-10-03	Yuji Makino	Preparation for intratracheobronchial administration
US5830853A (en)	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US6794357B1 (en)	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
SK283569B6 (sk) *	1993-10-01	2003-09-11	Astra Aktiebolag	Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
IS1736B (is)	1993-10-01	1999-12-30	Astra Ab	Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9322014D0 (en)	1993-10-26	1993-12-15	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
NL9301851A (nl) *	1993-10-26	1995-05-16	Cordis Europ	Cryo-ablatie catheter.
GB9404945D0 (en)	1994-03-15	1994-04-27	Glaxo Group Ltd	Pharmaceutical composition
US6102036A (en) *	1994-04-12	2000-08-15	Smoke-Stop	Breath activated inhaler
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
DE4425255A1 (de)	1994-07-16	1996-01-18	Asta Medica Ag	Formulierung zur inhalativen Applikation
CA2206657C (en)	1994-12-22	2009-05-19	Astra Aktiebolag	Therapeutic preparation for inhalation containing parathyroid hormone, pth
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
EP0806940B1 (en)	1994-12-22	2003-04-09	AstraZeneca AB	Aerosol drug formulations
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
PL189855B1 (pl) *	1997-05-27	2005-09-30	Direct Haler As	Urządzenie do podawania sproszkowanej substancji aktywnej
KR100609646B1 (ko)	1998-08-18	2006-08-04	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	Ｅｇｆ-ｒ 길항물질의 투여에 의한 기도 점액생산의 방지
US7354894B2 (en)	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
MXPA01012533A (es)	1999-06-05	2003-10-14	Innovata Biomed Ltd	Sistema de suministro.
ITMI991582A1 (it)	1999-07-16	2001-01-16	Chiesi Farma Spa	Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
GB9920839D0 (en)	1999-09-04	1999-11-10	Innovata Biomed Ltd	Inhaler
EP1129705A1 (en) *	2000-02-17	2001-09-05	Rijksuniversiteit te Groningen	Powder formulation for inhalation
GB0009469D0 (en)	2000-04-17	2000-06-07	Vectura Ltd	Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es)	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ATE275391T1 (de) *	2000-10-12	2004-09-15	Boehringer Ingelheim Pharma	Neue tiotropium-haltige inhalationspulver
UA75375C2 (en)	2000-10-12	2006-04-17	Boehringer Ingelheim Pharma	Method for producing powdery preparations for inhaling
US20060194773A1 (en) *	2001-07-13	2006-08-31	Paratek Pharmaceuticals, Inc.	Tetracyline compounds having target therapeutic activities
DE10141377A1 (de) *	2001-08-23	2003-03-13	Boehringer Ingelheim Pharma	Aufstreuverfahren zur Herstellung von Pulverformulierungen
WO2003024396A2 (en) *	2001-09-17	2003-03-27	Glaxo Group Limited	Dry powder medicament formulations
CN1607941A (zh) *	2001-11-19	2005-04-20	贝克顿迪肯森公司	粒状药物组合物
GB0128148D0 (en)	2001-11-23	2002-01-16	Innovata Biomed Ltd	Assembly
US6900317B2 (en) *	2002-02-19	2005-05-31	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20040014679A1 (en) *	2002-02-20	2004-01-22	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
DE10207026A1 (de) *	2002-02-20	2003-08-28	Boehringer Ingelheim Kg	Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
JP2006516531A (ja) *	2002-08-21	2006-07-06	ノートン　ヘルスケアー　リミテッド	吸入組成物
DE10255387A1 (de) *	2002-11-28	2004-06-09	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Tiotropium-haltige Pulverformulierung für die Inhalation
US7763280B2 (en)	2002-11-28	2010-07-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tiotropium containing powder formulation for inhalation
DE10317461A1 (de)	2003-04-16	2004-10-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
US20050042179A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE10338402A1 (de) *	2003-08-18	2005-03-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338407A1 (de) *	2003-08-18	2005-03-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338399A1 (de) *	2003-08-18	2005-03-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
US20050042178A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US20050043247A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
DE10338403A1 (de) *	2003-08-18	2005-03-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
SI1699434T1 (sl)	2003-09-02	2011-06-30	Norton Healthcare Ltd	Postopek za pripravo zdravila
PE20050489A1 (es)	2003-11-04	2005-09-02	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
JP2007533387A (ja)	2004-04-21	2007-11-22	イノベータバイオメドリミテッド	吸入器
GB0409197D0 (en)	2004-04-24	2004-05-26	Innovata Biomed Ltd	Device
PE20060259A1 (es)	2004-04-27	2006-03-25	Glaxo Group Ltd	Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
US7723306B2 (en) *	2004-05-10	2010-05-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) *	2004-05-10	2010-06-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) *	2004-05-10	2009-11-03	Boehringer Ingelheim Pharma Gmbh And Co. Kg	1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004048389A1 (de) *	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
DE102004048390A1 (de) *	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
WO2006086270A1 (en) *	2005-02-10	2006-08-17	Glaxo Group Limited	Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
WO2010010538A2 (en)	2008-07-24	2010-01-28	L'air Liquide-Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude	Heteroleptic cyclopentadienyl transition metal precursors for deposition of transition metal-containing films
US9925282B2 (en)	2009-01-29	2018-03-27	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
LT2400950T (lt)	2009-02-26	2019-08-26	Glaxo Group Limited	Farmacinės kompozicijos, apimančios 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzil)oksi]etoksi}heksil)amino]-1-hidroksetil}-2-(hidroksimetil)fenolį
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
PT106094A (pt)	2012-01-13	2013-07-15	Hovione Farmaciencia S A	Administração por inalação de formulações com dose elevada
WO2014007773A1 (en) *	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Compositions comprising muscarinic receptor antagonist and sorbitol
WO2014007772A2 (en)	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Inhalation compositions comprising glucose anhydrous
US20150174064A1 (en) *	2012-07-05	2015-06-25	Arven IIac Sanayi Ve Ticaret A.S.	Compositions comprising muscarinic receptor antagonist and glucose anhydrous
WO2014007771A2 (en)	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Inhalation compositions comprising muscarinic receptor antagonist
CA2889446C (en)	2012-10-25	2021-05-11	The General Hospital Corporation	Combination therapies for the treatment of alzheimer's disease and related disorders
GB201305825D0 (en)	2013-03-28	2013-05-15	Vectura Ltd	New use
US10525005B2 (en)	2013-05-23	2020-01-07	The General Hospital Corporation	Cromolyn compositions and methods thereof
US10307370B2 (en)	2013-10-08	2019-06-04	AI Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
AU2014340182B2 (en) *	2013-10-22	2019-05-23	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
DK3125875T3 (da)	2014-04-04	2023-07-24	Ai Therapeutics Inc	Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
KR20170095807A (ko)	2014-10-07	2017-08-23	램 테라퓨틱스, 인코포레이티드	폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
CA3033079A1 (en)	2016-08-31	2018-03-08	The General Hospital Corporation	Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
MY200258A (en)	2017-06-28	2023-12-17	Philip Morris Products Sa	Container with particles for use with inhaler
JP7202376B2 (ja)	2017-07-20	2023-01-11	エーゼットセラピーズ，インコーポレイテッド	クロモリンナトリウムおよびイブプロフェンの粉末製剤
KR20210071943A (ko)	2018-07-02	2021-06-16	더 제너럴 하스피탈 코포레이션	크로몰린 소듐 및 α-락토스의 분말화된 제형
ES2953293T3 (es)	2018-08-07	2023-11-10	Norton Waterford Ltd	Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
WO2020123449A1 (en)	2018-12-10	2020-06-18	The General Hospital Corporation	Cromolyn esters and uses thereof
EP4132507A4 (en)	2020-04-06	2024-05-15	The General Hospital Corporation	Methods of treatment of coronavirus-induced inflammation conditions
WO2022043481A1 (en)	2020-08-28	2022-03-03	Universität Linz	Use of leoligin in the prevention of tissue damage
WO2026002967A1 (en)	2024-06-24	2026-01-02	Universität Linz	Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1792207U (de)	1959-04-14	1959-07-16	Esslinger Sack Und Planenfabri	Transportables gartenschwimm- oder -planschbecken mit aus kunststoff-folie bestehenden waenden.
FR1489749A (fr)	1965-03-25	1967-07-28	Fisons Pharmaceuticals Ltd	Procédé de préparation de composés bis-chromonylés et leurs dérivés

1967
- 1967-08-08 GB GB36270/67A patent/GB1242211A/en not_active Expired
1968
- 1968-07-25 IE IE898/68A patent/IE32343B1/xx unknown
- 1968-07-30 FI FI682158A patent/FI48973C/fi active
- 1968-07-31 BE BE718846D patent/BE718846A/xx not_active IP Right Cessation
- 1968-07-31 US US748937A patent/US3634582A/en not_active Expired - Lifetime
- 1968-08-01 CA CA026,437A patent/CA946280A/en not_active Expired
- 1968-08-02 NL NL6811060.A patent/NL161984C/xx not_active IP Right Cessation
- 1968-08-03 DE DE1792207A patent/DE1792207C3/de not_active Expired
- 1968-08-03 DE DE19681792799 patent/DE1792799A1/de not_active Ceased
- 1968-08-07 FR FR162134A patent/FR8142M/fr not_active Expired
- 1968-08-07 DK DK380968AA patent/DK123276B/da unknown
- 1968-08-07 NO NO03102/68A patent/NO128307B/no unknown
- 1968-08-07 SE SE6810634A patent/SE372420B/xx unknown
- 1968-08-21 FR FR163601A patent/FR1605538A/fr not_active Expired
1971
- 1971-04-14 JP JP2321371A patent/JPS5643448B1/ja active Pending
1974
- 1974-12-30 MY MY329/74A patent/MY7400329A/xx unknown
- 1974-12-30 MY MY330/74A patent/MY7400330A/xx unknown

Also Published As

Publication number	Publication date
BE718846A (2)	1969-01-31
DE1792207A1 (de)	1971-11-04
MY7400330A (en)	1974-12-31
FR8142M (2)	1970-08-17
DE1792799A1 (de)	1977-08-11
CA946280A (en)	1974-04-30
US3634582A (en)	1972-01-11
IE32343L (en)	1969-02-08
DK123276B (da)	1972-06-05
FI48973B (2)	1974-12-02
DE1792207C3 (de)	1978-06-29
DE1792207B2 (de)	1977-10-13
SE372420B (2)	1974-12-23
NO128307B (2)	1973-10-29
GB1242211A (en)	1971-08-11
NL6811060A (2)	1969-02-11
FR1605538A (2)	1979-02-23
NL161984B (nl)	1979-11-15
NL161984C (nl)	1980-04-15
MY7400329A (en)	1974-12-31
JPS5643448B1 (2)	1981-10-13
FI48973C (fi)	1975-03-10

Publication	Publication Date	Title
IE32343B1 (en)	1973-06-27	Pharmaceutical composition
EP0322137B1 (en)	1992-05-27	Spray dried ibuprofen
US5547683A (en)	1996-08-20	Method for producing microgranulated particle
Zeng et al.	1998	The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro
US3882228A (en)	1975-05-06	Analgesic formulations
EP0203768B1 (en)	1990-08-01	A therapeutic effervescent composition and a method of preparing the same
DE69915478T2 (de)	2005-01-13	Geschmacksmaskierung mittels croscarmellose
JP2550362B2 (ja)	1996-11-06	スプレードライしたアセトアミノフェン
US4757090A (en)	1988-07-12	Direct tableting acetaminophen compositions
KR840000226A (ko)	1984-02-18	신규한 형태의 의약품의 제조방법
GB1381872A (en)	1975-01-29	Pharmaceutical compositions for inhalation
CA2166109A1 (en)	1995-01-05	Compositions for inhalation
CA2166891A1 (en)	1995-01-19	Method for making freeze dried drug dosage forms
NO20001670L (no)	2000-05-22	Fremgangsmate for fremstilling av en smaksmaskert farmasoytisk blanding og smaksmaskert farmasoytisk blanding fremstilt ifolge denne fremgangsmaten, samt smaksmaskerte tyggbare tabletter
GB2237510B (en)	1993-09-15	Small particle drug compositions for nasal administration
HU225964B1 (en)	2008-01-28	Moisture barrier film coating composition, method, and coated form
JPWO1994008709A1 (ja)	1994-11-02	微細な造粒体の製造方法
CA2430318A1 (en)	2002-06-06	Powder formulation and method for producing the same
CA2008972A1 (en)	1990-08-14	Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
CA1324083C (en)	1993-11-09	Pharmaceutical preparations containing non-steroidal anti-inflammatory agents
US6391340B1 (en)	2002-05-21	Dry powder pharmaceutical formulation
KR20000070189A (ko)	2000-11-25	0.28 내지 0.38 ｇ/㎖의 유동 벌크 밀도를 갖는 테르부탈린 술페이트 함유 신규 흡입 제제, 그의 제조 방법 및 그의 용도
JPH0461853B2 (2)	1992-10-02
JPH0967247A (ja)	1997-03-11	均一な微粒子製剤の製造方法
GB1511852A (en)	1978-05-24	Reconstitutable powders